Dr. Morgan on BCMA-Targeted ADCs in Multiple Myeloma

Publication
Video
Supplements And Featured PublicationsYear in Review: Evolving Landscape in Multiple Myeloma
Volume 1
Issue 1

Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research, NYU Langone Health’s Perlmutter Cancer Center, discusses BCMA-targeted antibody-drug conjugates (ADCs) in multiple myeloma.

Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research, NYU Langone Health’s Perlmutter Cancer Center, discusses BCMA-targeted antibody-drug conjugates (ADCs) in multiple myeloma.

ADCs are designed to provide a direct means of killing malignant cells, explains Morgan. The drug that is the furthest along in development is belantamab mafodotin, where monomethyl auristatin F (MMAF) is linked to a BCMA antibody. The linker transports MMAF to the malignant cell, and kills it by inhibiting its spindle, explains Morgan.

Findings from the phase I DREAMM-1 trial and phase II DREAMM-2 trial are very encouraging, says Morgan. In the DREAMM-2 trial, more than 30% of patients experienced durable responses with belantamab mafodotin. Although there is concern for ocular toxicity that can lead to keratopathy, investigators are evaluating alternative dosing schedules to reduce this risk, concludes Morgan.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Martin H. Voss, MD, an expert on renal cell carcinoma
Laurence Albigès, MD, PhD, an expert on renal cell carcinoma
A panel of 4 experts on hematologic malignancies